NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

You have got to be kidding, right? No offense to skitahoe, but just about everything in that post you’re replying to is wrong.

- The current manual production process is “open” which means there can not be more than one patient’s cells in a clean room at a time.

- There are not “cell lines.” This is a personalized cell therapy, so there is only a single patient’s cells.

- There are no robots!!!!!!

- DCVax-Direct has it own patented process that uses a bagged culture system, not the flask culture system used in the Flaskworks’ system. It likely requires this bagged system for the delayed maturation process.

- The Flaskworks’s system cannot be stacked.

- Elon Musk is not developing robots to service multiple Flaskworks devices!!!!! (this has to be a joke)

—————————————

Why do you think there were other companies that wanted the Flaskworks’ technology? It’s specialized to close and automate the culturing process strictly for dendritic cells, which makes it a pretty small group of companies that would even be interested. It seemed like a pretty routine acquisition according to the filing, and no mention of a bidding war.

Are you saying that you think Charles Rivers Labs is working with the Flaskworks’ equipment? And you’re guaranteeing this?

I doubt they are doing parallel equivalency runs with the Flaskworks’ system yet. The current production is in London, so these can’t be started until after Sawston is certified. You’ll notice Northwest has stated that initial practice runs and optimization of the Flaskworks system MAY begin this summer, and then a regulatory validation process will occur after sufficient practice runs have been completed. This is a major process change that will require an extensive equivalency study, which unfortunately won’t be “quick.”